CYTOKINE BLOOD PROFILE IN PATIENTS WITH DIFFUSE LIVER DISEASE COMBINED WITH EPSTEIN-BARR VIRUS AND SECONDARY IMMUNODEFICIENCY

Abstract

The aim of the paper is to study cytokine blood profile (CBP) in patients with chronic diffuse liver disease (DLD) associated with the Epstein-Barr virus (EBV) and secondary immunodeficiency (SID), using a combination of drugs with hepatoprotective (arginine glutamate) and immunomodulatory effects (aminodihydrophthalazinedione sodium). Materials and Methods. The authors examined 66 patients, aged 19–45, with DLD, associated with EBV and SID. The main group consisted of 34 patients, whereas the experimental group enrolled 32 patients. When developing a therapy program for such patients the authors paid attention to a combination of drugs with hepatoprotective (arginine glutamate) and immunomodulatory effects (aminodihydrophthalazinedione sodium). Patients from the main group, in addition to conventional therapy, received combined therapy with the above-mentioned drugs. Results. All patients were under dynamic observation. Before treatment, patients of both groups had similar CBP imbalance, which was characterized by an increase in pro-inflammatory cytokines – TNF-α and IL-1β and a moderate increase in anti-inflammatory IL-4 and IL-10. After treatment, patients of the main group, who received aminodihydrophthalazinedione sodium and arginine glutamate, demonstrated normalization in CBP parameters, while the parameters of the patients from the comparison group exceeded the norm. Conclusion. Combined therapy in the complex treatment of patients with chronic DLD, combined with EBV and SID, contributes to the normalization of the studied CBP parameters (TNF-α, IL-1β, IL-4, IL-10).